On October 5, PharmaEssentia announced consolidated revenue for September at NT$930 million, marking a 3.4% monthly growth and a remarkable 132.05% year-on-year increase, continuing its strong growth momentum. This marks the fifth consecutive month of record-breaking revenue, with the primary contributor being the U.S. sales of the company’s rare blood cancer drug, Ropeginterferon alfa-2b (Ropeg). Cumulative revenue for the first three quarters has reached NT$6.67 billion, reflecting a 92.94% year-on-year increase. The company remains optimistic about its operational outlook for Q4 and is confident in continued future growth.
As for the much-anticipated Ropeg prefilled pen injector, PharmaEssentia has received notification from the U.S. Food and Drug Administration (FDA) that a decision on whether the submission will proceed to formal review will be made within 60 days of submission. If no additional information is required, the target Prescription Drug User Fee Act (PDUFA) date for the Ropeg prefilled pen is set for January 10, 2025. PharmaEssentia is fully cooperating with the FDA's review process to bring the Ropeg prefilled pen to market as soon as possible.
In the Japanese market, Ropeg’s performance has also been outstanding. Since June, Japanese health insurance policies have allowed patients to self-administer Ropeg, with up to a 90-day supply per prescription. This policy has significantly increased patient willingness to use the drug, boosting revenues in Japan. Additionally, PharmaEssentia's Japanese subsidiary launched a home delivery service for medications on October 1, making it easier for patients to obtain their treatment and further expanding the market in Japan.
Since its launch, PharmaEssentia’s self-developed drug Ropeg has steadily gained global market share, repeatedly achieving record revenues and receiving recognition in the stock market. In June of this year, PharmaEssentia was included in Taiwan’s Medium Cap 100 Index, and in September, it rose to become one of the top 50 companies by market capitalization on the Taiwan Stock Exchange. As the only biotech stock included in both the Taiwan 50 and Fubon Taiwan 50 ETFs, this highlights the company's strong potential and growth momentum within the pharmaceutical industry.
Resource (mandarin): 藥華藥營收連五月創新高 年增132%、前九月增九成
